Krazati (adagrasib) demonstrated statistically significant improvement in progression free survival in patients with pretreated locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer.- BMS
Bristol Myers Squibb announced results from the Phase III KRYSTAL-12 study evaluating Krazati (adagrasib) compared to standard of care chemotherapy in patients with locally advanced or metastatic KRASG12C -mutated non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy, concurrently or sequentially with anti-PD-(L)1 therapy.
At a median follow-up of 9.4 months, Krazati demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), the study’s primary endpoint, as assessed by Blinded Independent Central Review (BICR) compared to docetaxel (HR: 0.58; [95% CI, 0.45-0.76]; P <0.0001). median pfs was 5.5 months for krazati compared to 3.8 months for docetaxel. overall response rate (orr) as assessed by bicr was also significantly higher with krazati compared to docetaxel (32% vs 9%; odds ratio, 4.68; p>< 0.0001). The median duration of response (mDOR) was 8.31 months (95% CI, 6.05–10.35) versus 5.36 months (95% CI, 2.86–8.54), respectively.
Krazati demonstrated intracranial response among patients with central nervous system (CNS) metastases at baseline, with a response rate per BICR that was more than double that observed with docetaxel (24% with Krazati vs. 11% with docetaxel).
The KRYSTAL-12 study remains ongoing to assess the additional key secondary endpoint of overall survival.
No new safety signals were identified for Krazati, and the safety data were consistent with the known safety profile. Treatment-related adverse events (TRAEs) of any grade were reported in 94% of patients treated with Krazati and 86.4% with docetaxel. Grade ?3 TRAEs occurred in 47% and 46% of patients, respectively.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.